Experience

CanSino Biologics Inc.康希诺生物

• Biotechnology Research
• 1 - 100 Employee

• 项目管理办公室总监

  • Apr 2023 - Present

• SFE director

  • Sep 2022 - Apr 2023

  Responsible for SFE management including territory, sales target, incentive, CRM and related projects.


Sanofi Pasteur
• Pharmaceutical Manufacturing
• 200 - 300 Employee
• New Vaccine Portfolio Planning Senior Manager

  • Sep 2019 - Aug 2022


Nestlé Skin Health

• Switzerland
• Wellness and Fitness Services
• 700 & Above Employee

• Senior Strategic Planning Manager

  • Jun 2018 - Sep 2019

  • Strategic and Launch Planning: 1) Portfolio strategy development, new product launch planning, execution of organization plansand proactive preparation of deliverables. 2) Investigate local market research and global strategy, participate and improve the 5 years market strategy and planning. • Commercial Operation: Perform analytics to commercial and distribution business provide business improvement suggestion and scheme. • Business Acquisition: Evaluate and provide suggestion to local and global business acquisitions. Show less



辉瑞

• 1 - 100 Employee

• Commercial Effectiveness Manager

  • Mar 2017 - Jun 2018

  Commercial Effectiveness Mgr: 1) Consolidate and automate integrated commercial effectiveness system 2) Investigate business drivers 3) Customize operation excellence strategy and projects. Commercial Effectiveness Mgr: 1) Consolidate and automate integrated commercial effectiveness system 2) Investigate business drivers 3) Customize operation excellence strategy and projects.



雀巢

• China
• Food and Beverage Services
• 1 - 100 Employee

• Operation Efficiency Manager

  • Apr 2014 - Mar 2017

  1) Lead the “Strategic to Execution” transformation from analysis and industrial report. 2) Establish ISV “Activity Management System” 3) Veeva global program landing in China. 4) SOP and Compliance enhancement 1) Lead the “Strategic to Execution” transformation from analysis and industrial report. 2) Establish ISV “Activity Management System” 3) Veeva global program landing in China. 4) SOP and Compliance enhancement



默克雪兰诺

• China
• Wholesale
• 1 - 100 Employee

• Sales and Product Manager

  • May 2012 - Apr 2014

  Product and Sales Manager – Launched rare disease product promotion and sales• Hospital: Rare Disease product listed in 8 key accounts progress.• Pharmacy: Distributed in assigned pharmacies and keep supplement.• Diagnose: 2013, published Beijing PKU diagnose guideline with KOLs.• KOL management: Managed over 30 KOLs for academic, diagnosed, prescription by detailing, studies, oversea and local congress supports.

• Market Access Supervisor

  • Apr 2011 - May 2012

  Market Access Supervisor – Managed rare disease product China accessed and launchedDirect Report: Government Affair Director Dotline Report: Global Rare Disease Marketing Head• Market Access: Learn product and disease related policies linked to company strategy and local policy to ensure smooth accessing. In 2012, product was negotiated and listed in Qingdao. In 2013, product was listed in New Rural list with 60% reimbursed ratio.• Policies: Interpret the central and regional policies of serious and rare disease to guide the product listed or reimbursed.• Patient Access: Setup and manage PAP program. From 2011 to 2013,launched project assisting 80 children in 21 middle and western provinces, cooperating with NHFPC.• Government Relationship: o NHFPC: for health education projects and corporations, and learning updated policy that potentially driven business or listing progress and chances.o MOHRSS: negotiated for regional reimbursement and product assess.o NDRC: learn and influence product pricing and policies, to keep the pricing stable and to influence or adapt to the government policy changed.o CFDA: for drug test before launch or sales, ensure supply chain and sales planning. Show less

• Commercial Supervisor

  • Mar 2009 - Mar 2011

  1/Commercial distributior management.2/Guangdong, Guangxi Provincial Tendering management and negotiation.3/OTC channel promotion and sales.